Skip to main content

AML, Adult

2
Pipeline Programs
7
Companies
9
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 8 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Ascentage Pharma
Ascentage PharmaChina - Beijing
1 program
1
APG 2575 ramp up armPhase 1/21 trial
Active Trials
NCT04964518Unknown24Est. Oct 2024
Stelexis Therapeutics
1 program
1
EganelisibPhase 1Small Molecule1 trial
Active Trials
NCT06533761Recruiting125Est. Mar 2028
Qihan Biotech
Qihan BiotechChina - Hangzhou
4 programs
CD33/CLL1 dual CAR-NK cellPHASE_11 trial
QN-023aPHASE_11 trial
QN-023aPHASE_11 trial
QN-030aPHASE_11 trial
Active Trials
NCT05987696Completed2Est. Jan 2025
NCT05601466Terminated3Est. Apr 2023
NCT05665075Unknown19Est. Dec 2025
+1 more trials
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
IL-6: A Marker for AML Chemo SensitivityN/A1 trial
Active Trials
NCT06486350Recruiting72Est. Jun 2025
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
chidamide and azacitidineN/A1 trial
Active Trials
NCT06066905Recruiting60Est. Dec 2026
FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
1 program
FF-10101-01PHASE_11 trial
Active Trials
NCT03194685Completed97Est. Jul 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Ascentage PharmaAPG 2575 ramp up arm
Stelexis TherapeuticsEganelisib
Qihan BiotechCD33/CLL1 dual CAR-NK cell
Qihan BiotechQN-023a
Qihan BiotechQN-030a
Qihan BiotechQN-023a
FUJIFILM PharmaFF-10101-01
Chipscreen Bioscienceschidamide and azacitidine
UNION therapeuticsIL-6: A Marker for AML Chemo Sensitivity

Clinical Trials (9)

Total enrollment: 420 patients across 9 trials

NCT04964518Ascentage PharmaAPG 2575 ramp up arm

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Start: Jul 2021Est. completion: Oct 202424 patients
Phase 1/2Unknown
NCT06533761Stelexis TherapeuticsEganelisib

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Start: Apr 2025Est. completion: Mar 2028125 patients
Phase 1Recruiting
NCT05987696Qihan BiotechCD33/CLL1 dual CAR-NK cell

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Start: Jul 2023Est. completion: Jan 20252 patients
Phase 1Completed
NCT05665075Qihan BiotechQN-023a

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Start: Dec 2022Est. completion: Dec 202519 patients
Phase 1Unknown
NCT05665114Qihan BiotechQN-030a

Natural Killer(NK) Cell Therapy in r/r AML

Start: Dec 2022Est. completion: Dec 202518 patients
Phase 1Unknown
NCT05601466Qihan BiotechQN-023a

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Start: Mar 2022Est. completion: Apr 20233 patients
Phase 1Terminated
NCT03194685FUJIFILM PharmaFF-10101-01

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start: May 2017Est. completion: Jul 202197 patients
Phase 1Completed
NCT06066905Chipscreen Bioscienceschidamide and azacitidine

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Start: Oct 2023Est. completion: Dec 202660 patients
N/ARecruiting
NCT06486350UNION therapeuticsIL-6: A Marker for AML Chemo Sensitivity

IL-6: A Marker for AML Chemo Sensitivity

Start: Oct 2023Est. completion: Jun 202572 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 420 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.